Isolation and transplantation of highly purified autologous peripheral CD34 + progenitor cells: Purging efficacy, hematopoietic reconstitution following high dose chemotherapy in patients with breast cancer: Results of a feasibility study in Japan

被引:8
作者
Chou T. [1 ]
Sano M. [2 ]
Ogura M. [3 ]
Morishima Y. [3 ]
Itagaki H. [4 ]
Tokuda Y. [5 ]
机构
[1] Department Internal Medicine, Niigata Cancer Center Hospital, Niigata City, Niigata 951-8566
[2] Department of Surgery, Niigata Cancer Center Hospital, Niigata
[3] Department Hematology and Cell Therapy, Aichi Cancer Center, Aichi
[4] Department Cell Transplantation and Regenerative Medicine, Kanagawa
[5] Department Surgery, Tokai University, School of Medicine, Kanagawa
关键词
Breast cancer; CD34-positive selection; High-dose chemotherapy; Magnetic-cell sorting system; Peripheral blood stem cells;
D O I
10.2325/jbcs.12.178
中图分类号
学科分类号
摘要
Background: High-dose chemotherapy with autologous stem cell support may have some therapeutic impact on certain groups of the patients with advanced breast cancer (BRCA). Since stem cell contamination by tumor cells might contribute to relapse, development of a tumor cell purging technique would improve the clinical outcome. The present study was undertaken to evaluate the purging efficacy of autologous mobilized CD34 + peripheral stem cells in patients with breast cancer (BRCA) in an advanced stage or relapse. Methods: CD34 + cells were selected from autologous peripheral blood stem cells (PBSC) using a clinical scale of magnetic-activated cell sorting system (CliniMACS), followed by high-dose chemotherapy with transplantation of CD34 + selected cells. Amplification of cytokeratin 19 (CK19) and 20 (CK20) gene in leukapheresis products were measured to evaluate the performance of tumor cell elimination. Results: Seven patients were entered into this study. After leukopheresis, 1 patient was dropped form this study due to poor mobilization. Among 6 patient, a total of 8 CD34 + selection was performed. The median purity and recovery rate of the CD34 + cells post selection was 85.1% (range 62.5-98.1%) and 74.2% (range 50.2-90.2%), respectively. After isolation of CD34 + cells, the elimination rate in the logarithmic transformation of CK19 was 2.77 log, and that of CK20 were 2.43 log and 2.53 log. In 4 patients, high-dose chemotherapy was performed, followed by the transplantation of the isolated CD34 + cells. Rapid neutrophil recovery, as well as platelet recovery was seen with a median time to reach 0.5 × 10 9/1 neutrophils of 9 days (range 8-9), and 20 × 10 9/1 platelets of 12 days (range 10-13). There was no treatment related death and no serious adverse events directly associated with the selection procedure or infusion of selected cells. Conclusions: The present study demonstrated that the CliniMACS system is a highly effective positive selection method and that a high purging efficacy could be obtained without compromising the hematopoietic reconstitution capacity of the graft in BRCA patients undergoing high-dose chemotherapy.
引用
收藏
页码:178 / 188
页数:10
相关论文
共 37 条
[1]  
Antman K.H., Rowlings P.A., Vaughan W.P., Pelz C.J., Fay J.W., Fields K.K., Freytes C.O., Gale R.P., Hillner B.E., Holland H.K., Kennedy M.J., Klein J.P., Lazarus H.M., McCarthy Jr. P.L., Saez R., Spitzer G., Stadtmauer E.A., Williams S.F., Wolff S., Sobocinski K.A., Armitage J.O., Horowitz M.M., High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America, Journal of Clinical Oncology, 15, 5, pp. 1870-1879, (1997)
[2]  
Bokemeyer C., Kollmannsberger C., Meisner C., Harstrick A., Beyer J., Metzner B., Hartmann J.T., Schmoll H.-J., Einhorn L., Kanz L., Nichols C., First-line high-dose chemotherapy compared with standard-dose PEB/VIP chemotherapy in patients with advanced germ cell tumors: A multivariate and matched-pair analysis, Journal of Clinical Oncology, 17, 11, pp. 3450-3456, (1999)
[3]  
Pritchard J., McElwain T.J., Graham-Pole J., High-dose melphalan with autologous marrow for treatment of advanced neuroblastoma, British Journal of Cancer, 45, 1, pp. 86-94, (1982)
[4]  
Ross A.A., Cooper B.W., Lazarus H.M., Mackay W., Moss T.J., Ciobanu N., Tallman M.S., Kennedy M.J., Davidson N.E., Sweet D., Winter C., Akard L., Jansen J., Copelan E., Meagher R.C., Herzig R.H., Klumpp T.R., Kahn D.G., Warner N.E., Detection and viability of tumor cells in peripheral blood stem cell collections from breast cancer patients using immunocytochemical and clonogenic assay techniques, Blood, 82, 9, pp. 2605-2610, (1993)
[5]  
Ross A.A., Loudovaris M., Hazelton B., Weaver C.H., Schwartzberg L., Bender J.G., Immunocytochemical analysis of tumor cells in pre- and post-culture peripheral blood progenitor cell collections from breast cancer patients, Experimental Hematology, 23, 14, pp. 1478-1483, (1995)
[6]  
Brugger W., Bross K.J., Glatt M., Et al., Mobilization of tumor cells and hematopoietic progenitor cells into peripheral blood of patients with solid tumors, Blood, 83, pp. 636-640, (1995)
[7]  
Handgretinger R., Greil J., Schurmann U., Et al., Positive selection and transplantation of peripheral CD34 <sup>+</sup> progenitor cells: Feasibility and purging efficacy in pediatric patients with neuroblastoma, J Hematother, 6, pp. 235-242, (1997)
[8]  
Leung W., Chen A.R., Klann R.C., Moss T.J., Davis J.M., Noga S.J., Cohen K.J., Friedman A.D., Small D., Schwartz C.L., Borowitz M.J., Wharam M.D., Paidas C.N., Long C.A., Karandish S., McMannis J.D., Kastan M.B., Civin C.I., Frequent detection of tumor cells in hematopoietic grafts in neuroblastoma and Ewing's sarcoma, Bone Marrow Transplantation, 22, 10, pp. 971-979, (1998)
[9]  
Miltenyi S., Muller W., Weichel W., Radbruch A., High gradient magnetic cell separation with MACS, Cytometry, 11, 2, pp. 231-238, (1990)
[10]  
Miltenyi S., Guth S., Radbruch A., Et al., Isolation of CD34 <sup>+</sup> hematopoietic progenitor cells by high-gradient magnetic cell sorting (MACS). Hematopietic stem cells, The Mulhouse Manual, pp. 201-213, (1994)